Richard W. Pascoe served as CEO of Zevra Therapeutics, Inc. until June 2023. He has a strong background in the pharmaceutical field, holding a B.S. from the United States Military Academy at West Point. Pascoe's tenure saw significant insider trading...

Richard W. Pascoe served as CEO of Zevra Therapeutics, Inc. until June 2023. He has a strong background in the pharmaceutical field, holding a B.S. from the United States Military Academy at West Point. Pascoe's tenure saw significant insider trading activity, reflecting his active engagement with the company's stock. In 2023 alone, he executed trades worth around $151,000 to $190,000 per month, showcasing confidence in his company's prospects. Prior to Zevra, he worked with Seelos Therapeutics, expanding his experience in the biotech sector. In 2023, his total compensation was approximately $4.12 million; however, it is notable that he did not receive a bonus as his tenure ended, marking a shift in incentives. Richard brings a military discipline to his leadership style, focusing on results and strategic long-term goals rather than short-term rewards. His career path in the pharmaceutical industry illustrates his commitment to healthcare advancements and innovation. His role reflects how executive compensation aligns with performance in this demanding field of biotechnology and therapeutics.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Zevra Therapeutics, Inc. CEOs

Z

Richard W. Pascoe

Ex-CEO of Zevra Therapeutics, Inc.

Education

B.S. degree from the United States Military Academy at West Point

Sector of Economy

Healthcare

Born

January 1, 1965 - 60 years ago

CEO of Zevra Therapeutics, Inc. for

0 years 4 months (Jan 2023 - Jun 2023)

Previous Experience

President and Chief Executive Officer of Histogen Inc.

Rivals

Competitors/colleagues of Richard W. Pascoe

Holdings

See how much did Richard W. Pascoe make over time.

Richard W. Pascoe actively managed his stock in Zevra Therapeutics. Throughout 2023, his monthly trades ranged from about $134,000 to $190,000, indicating a strategic approach to his holdings. Pascoe's engagements suggest he had substantial confidence in the company's future within...

Richard W. Pascoe actively managed his stock in Zevra Therapeutics. Throughout 2023, his monthly trades ranged from about $134,000 to $190,000, indicating a strategic approach to his holdings. Pascoe's engagements suggest he had substantial confidence in the company's future within the competitive biotech landscape. His highest observable trade occurred in August 2024, where he traded shares valued at approximately $216,000. This fluctuation in activity shows his ongoing commitment and interest in Zevra's developments, aligning with his tenure as CEO. Over time, the value of his trades demonstrated a steady commitment to liquidating investments while securing sufficient cash flow. His overall strategy indicates a serious investment in the company's success during his leadership.

Mar 17, 2025

Z

shares

ZVRA @ $8.35

Insider Trading

See recent insider trades of Richard W. Pascoe.

ZVRA

$41.98K

ZVRA at $4.20/share

Mar 9, 2023

Purchase

Compensation History

See how much did Richard W. Pascoe make over time.

In 2023, Richard W. Pascoe's total compensation reached $4.12 million. This amount stems largely from a salary of $273,576 and the granting of 700,000 stock options, reflecting both his position and the company's compensation structure. Notably, he did not receive a bonus that year due to the conclusion of his employment, which is a significant departure from the typical executive pay structure. Prior years show fluctuating amounts, with his compensation being zero from 2014 to 2018, which indicates a period of limited or no formal remuneration as he transitioned through different roles in the pharmaceutical industry. The company's compensation philosophy prioritizes performance-based incentives and long-term value alignment, illustrating how executive rewards are linked to company growth. Despite the lack of bonuses and stock grants in the past few years, Pascoe's stock options suggest potential future value tied to the company's success. His earnings, derived from a blend of salary, options, and other compensation elements, provide insight into how executive packages are designed to motivate leadership while ensuring accountability.

Year

2023

Total Compensation

$653.10K

Salary

$273.58K

Board Justification

The compensation philosophy aims to attract, retain, and motivate talented executives, aligning their interests with those of the stockholders through performance-based incentives.

Bonus

$0.00

Board Justification

Mr. Pascoe was not eligible for a bonus for 2023 following the termination of his employment.

Other

$379.53K

Board Justification

This includes 401(k) employer matching contributions, cash severance payments, and COBRA premiums following his separation from the Company.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards were vested in 2023 as Mr. Pascoe's employment ended before any awards could vest.

Performance Metrics

Performance metrics for 2023 were based on the achievement of specified development, regulatory, and financial milestones.

Other Zevra Therapeutics, Inc. CEOs

Here are other CEOs of Zevra Therapeutics, Inc.

Christal M.M. Mickle

Founder and Ex-CEO of Zevra Therapeutics, Inc.

June 2023 - October 2023